An Update on Kaposi's Sarcoma: Epidemiology, Pathogenesis and Treatment

被引：49

作者：

Curtiss, Paul ^{[1
]}

Strazzulla, Lauren C. ^{[1
]}

Friedman-Kien, Alvin E. ^{[1
]}

机构：

[1] NYU, Sch Med, Ronald O Perelman Dept Dermatol, New York, NY 10003 USA

来源：

DERMATOLOGY AND THERAPY | 2016年 / 6卷 / 04期

关键词：

Acquired immunodeficiency syndrome; Human immunodeficiency virus; Immunosuppression; Kaposi's sarcoma; 1ST-LINE THERAPY; HUMAN-HERPESVIRUS-8; TRANSMISSION; DOXORUBICIN; TRENDS; ERA;

D O I：

10.1007/s13555-016-0152-3

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Kaposi's sarcoma is an angioproliferative neoplasm which has undergone considerable epidemiologic change since the original description by Moritz Kaposi in the late 1800s. This opportunistic neoplasm gained widespread notoriety within the US during the height of the AIDS epidemic, where it was frequently found co-occurring with opportunistic infections. With the advent of modern antiretroviral therapies, as well as an increasing number of individuals on immunosuppression for autoimmune disease or organ transplantation, the landscape of the immunocompromised individual has changed. It is now important for clinicians to be mindful of Kaposi's sarcoma manifesting in a growing variety of clinical contexts.

引用

页码：465 / 470

页数：6

共 36 条

[1]

ARCHIBALD CP, 1990, J ACQ IMMUN DEF SYND, V3, pS18

[2] Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma [J].

Bower, M ;

Nelson, M ;

Young, AM ;

Thirlwell, C ;

Newsom-Davis, T ;

Mandalia, S ;

Dhillon, T ;

Holmes, P ;

Gazzard, BG ;

Stebbing, J .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) :5224-5228

[3] Intralesional vincristine as first-line therapy for nodular lesions in classic Kaposi sarcoma: a prospective study in 151 patients [J].

Brambilla, L. ;

Bellinvia, M. ;

Tourlaki, A. ;

Scoppio, B. ;

Gaiani, F. ;

Boneschi, V. .

BRITISH JOURNAL OF DERMATOLOGY, 2010, 162 (04) :854-859

[4]

Centers for Disease Control (CDC), 1981, MMWR Morb Mortal Wkly Rep, V30, P305

[5] Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma during potent antiretroviral therapy [J].

Connick, E ;

Kane, MA ;

White, IE ;

Ryder, J ;

Campbell, TB .

CLINICAL INFECTIOUS DISEASES, 2004, 39 (12) :1852-1855

[6] Resolution of diffuse skin and systemic Kaposi's sarcoma in a renal transplant recipient after introduction of everolimus: a case report [J].

Detroyer, D. ;

Deraedt, K. ;

Schoffski, P. ;

Hauben, E. ;

Lagrou, K. ;

Naesens, M. ;

Delforge, M. -L. ;

Kuypers, D. .

TRANSPLANT INFECTIOUS DISEASE, 2015, 17 (02) :303-307

[7] Activity and safety of pegylated liposomal doxorubicin as first-line therapy in the treatment of non-visceral classic Kaposi's sarcoma: A multicenter study [J].

Di Lorenzo, Giuseppe ;

Kreuter, Alexander ;

Di Trolio, Rossella ;

Guarini, Attilio ;

Romano, Carmela ;

Montesarchio, Vincenzo ;

Brockmeyer, Norbert H. ;

De Placido, Sabino ;

Bower, Mark ;

Dezube, Bruce J. .

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2008, 128 (06) :1578-1580

[8] Role of pegylated lyposomal doxorubicin (PLD) in systemic Kaposi's sarcoma: A systematic review [J].

Di Trolio, R. ;

Di Lorenzo, G. ;

Delfinoi, M. ;

De Placido, S. .

INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2006, 19 (02) :253-263

[9] Molecular genetics of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) epidemiology and pathogenesis [J].

Dourmishev, LA ;

Dourmishev, AL ;

Palmeri, D ;

Schwartz, RA ;

Lukac, DM .

MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS, 2003, 67 (02) :175-+

[10]

Eltom MA, 2002, J NATL CANCER I, V94, P1204, DOI 10.1093/jnci/94.16.1204

← 1 2 3 4 →